ディペプチジルペプチダゼ-4は,血管新生依存および血管新生独立作用を通じて,慢性心不全における左心室機能障害を調節する
Toshimasa Shigeta1, Morihiko Aoyama, Yasuko K Bando
1Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Circulation
|October 5, 2012
まとめ
ディペプチジルペプチダゼ-4 (DPP4) 阻害は,血管機能と心臓の収縮性を改善することにより,心不全 (DHF) を逆転させます. 循環中のDPP4レベルは,DHFをモニタリングするためのバイオマーカーとして役立つ可能性があります.
科学分野:
- 心血管研究 循環器科の研究
- 薬理学 薬理学とは
- バイオケミストリー バイオケミストリー
背景:
- ディペプチジルペプチダゼ-4 (DPP4) 阻害は,急性心筋不全症に有益である.
- 冠動脈疾患のない慢性心不全 (CHF) でのDPP4の役割は十分に理解されていません.
研究 の 目的:
- ダイアストリック左心室機能不全 (DHF) に関するDPP4の役割を調査する.
- DHFの治療戦略としてDPP4抑制を調査する.
主な方法:
- ネズミと人間の心臓の毛細血管に局所化された膜に結合したDPP4.
- 糖尿病のラットと圧力過負荷のラットでDPP4の活性化を研究した.
- DHFの患者における循環中のDPP4活性評価.
主要な成果:
- 糖尿病はDPP4を活性化し,血管新生を減らし,MMP-2/TIMP-2比率経由で線維症を伴うDHFを引き起こす.
- DPP4抑制は,糖尿病性DHFとマイクロ血管病変を逆転させました.
- DPP4の阻害は,GLP-1/cAMP経路を通した圧力過負荷誘発のDHFを逆転させた.
- DHF患者における循環中のDPP4の活動は,冠動脈動脈の活動とエコーカルディオグラフィのパラメータと相関していた.
結論:
- DPP4の阻害は,局所的および全身的メカニズムを通じてDHFを逆転させます.
- DPP4の阻害は血管新生と心臓の収縮性に影響を及ぼします.
- 循環中のDPP4は,DHFをモニタリングするための潜在的なバイオマーカーである可能性があります.
関連する概念動画
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...